Nonprofit supporting research on the causes of, and treatments for, schizophrenia and bipolar disorder.
The Stanley Medical Research Institute has built a grantmaking profile around schizophrenia and bipolar disorder research, with a visible emphasis on neurovirology and treatment trials. In the recent grants list, its largest award was $2,564,105 to Johns Hopkins University - Rhy in Baltimore for neurovirology studies earmarked for Dr. Yolken, followed by repeated multi-year support at the same institution in 2024 and 2023. That pattern points to sustained backing for specific investigators rather than one-time project checks. The institute also funds clinical research through earmarked treatment-trial grants. Recent examples include awards to Sheppard Pratt in Baltimore, the University of Maryland Baltimore - Rb in Columbia, and the University of Pittsburgh in Pittsburgh. These grants are directed to named researchers such as Dr. Dickerson, Dr. Buchanan, and Dr. Nimgaonkar, showing a structure built around investigator-led projects. A second thread runs through its support for research infrastructure and related organizations. The Treatment Advocacy Center in Arlington received annual grants in 2023, 2024, and 2025 for yearly expenses, while Vanpelt Biosciences LLC in Montgomery Village received repeated support across neurovirology and treatment-trial work.
One clear cause area is neurovirology. The institute gave $588,013 in 2025 to Sheppard Pratt in Baltimore for neurovirology studies earmarked for Dr. Dickerson, and it also supported Vanpelt Biosciences LLC in Montgomery Village for neurovirology studies in 2023 and 2024. That places infection- and immune-related questions close to the center of its research agenda. Another major focus is treatment development for schizophrenia and bipolar disorder. Recent treatment-trial grants went to the University of Maryland Baltimore - Rb in Columbia for Dr. Buchanan, The Regents of the Univ of California in Los Angeles for Dr. Marder, and the University of Pittsburgh for Dr. Nimgaonkar and Dr. Chengappa. The foundation also backs infrastructure tied to psychiatric research. The Treatment Advocacy Center in Arlington received yearly-expense support in 2023, 2024, and 2025, indicating recurring institutional funding alongside project grants.
$3.8M
$93.3M
$6.3M
$6.7M
Most grants fall between $67K and $161K, with a median of $102K.
25th Percentile
$67K
Median
$102K
75th Percentile
$161K
MAREE J WEBSTER
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Typical grant size falls in a fairly tight middle range: the 25th percentile is $66,947, the median is $102,032, and the 75th percentile is $161,066. The recent awards show a mix of very large investigator awards and smaller project grants, which is consistent with earmarked research funding. Support is recurring rather than one-off in several cases. Johns Hopkins University - Rhy appears in 2023, 2024, and 2025; Sheppard Pratt appears in all three years as well; and the Treatment Advocacy Center received annual support across the same period. The institute does not make program-related investments and does not fund individuals directly; its grants are project-specific and institutional, with some support earmarked to named investigators.
Grant recipients are concentrated in the United States, with 30 grants recorded there. Maryland is the top state by grant count, and 40% of grants go to recipients in the HQ state. Baltimore appears repeatedly through Johns Hopkins University - Rhy and Sheppard Pratt, while Columbia, Arlington, Pittsburgh, Los Angeles, and Dallas also show up in the recent grants list. The distribution is regional rather than national in practice, even though some program descriptions allow international reach.
Its core focus is schizophrenia and bipolar disorder research, with recurring support for treatment trials, neurovirology, brain tissue and datasets, epidemiology, biomarker development, and immunology or infectious-disease questions related to mental illness.
Yes. Johns Hopkins University - Rhy appears in 2023, 2024, and 2025; Sheppard Pratt appears in each of those years too; and the Treatment Advocacy Center received annual-expense support in 2023, 2024, and 2025.
The 25th percentile grant is $66,947, the median is $102,032, and the 75th percentile is $161,066. Recent awards also include much larger project grants, such as a $2,564,105 neurovirology award to Johns Hopkins University - Rhy.
Yes for some programs. The treatment-trials program accepts unsolicited applications, and the small inquiry-based immunology and infectious-disease funding also accepts unsolicited inquiries after pre-screening. Other support, such as general research grants and supported organizations, is not open to unsolicited applications.
Maryland receives the most grants, and 40% of grants go to recipients in the HQ state. Baltimore is a frequent recipient city, along with Columbia and other U.S. research centers such as Pittsburgh, Los Angeles, Arlington, and Dallas.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Current and upcoming funding from Stanley Medical Research Institute that your nonprofit may be able to apply for.
Who can apply: Investigators interested in working on SMRI's core areas, particularly immunology and infectious disease in relation to mental illness, may inquire. SMRI does not operate a general grants program and projects are subject to pre-screening and funder interest.
Deadline: No deadline stated.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| JOHNS HOPKINS UNIVERSITY - RHY | BALTIMORE, MD | $2,564,105 | 2025 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.YOLKEN |
| SHEPPARD PRATT | BALTIMORE, MD | $588,013 | 2025 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.DICKERSON |
| UNIVERSITY OF MARYLAND BALTIMORE - RB | COLUMBIA, MD | $147,656 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.BUCHANAN |
| THE REGENTS OF THE UNIV OF CALIFORNIA | LOS ANGELES, CA | $126,223 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.MARDER |
| UNIVERSITY OF PITTSBURGH | PITTSBURGH, PA | $107,392 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.NIMGAONKAR AND DR.CHENGAPPA |
| TREATMENT ADVOCACY CENTER | ARLINGTON, VA | $99,005 | 2025 | TAC GRANT FOR YEARLY EXPENSES |
| THE MCLEAN HOSPITAL CORPORATION | BELMONT, MA | $89,197 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.ONGUR |
| VANPELT BIOSCIENCES LLC | MONTGOMERY VILLAGE, MD | $75,000 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.NIMGAONKAR |
| AUGUSTA UNIVERSITY RESEARCH INSTITUTE | HAPEVILLE, GA | $29,547 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.MILLER |
| UT SOUTHWESTERN MEDICAL CENTER - SB | DALLAS, TX | $18,079 | 2025 | TREATMENT TRIALS-EARMARKED FOR DR.BROWN |
| JOHNS HOPKINS UNIVERSITY - RHY | BALTIMORE, MD | $2,525,950 | 2024 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.YOLKEN |
| SHEPPARD PRATT | BALTIMORE, MD | $599,262 | 2024 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.DICKERSON AND TREATMENT TRIALS-EARMARKED FOR DR.DICKERSON |
| UNIVERSITY OF PITTSBURGH | PITTSBURGH, PA | $120,794 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR.NIMGAONKAR |
| THE REGENTS OF THE UNIV OF CALIFORNIA | LOS ANGELES, CA | $114,254 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR.MARDER |
| TREATMENT ADVOCACY CENTER | ARLINGTON, VA | $102,495 | 2024 | TAC GRANT FOR YEARLY EXPENSES |
| UNIVERSITY OF MARYLAND BALTIMORE - RB | COLUMBIA, MD | $101,570 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR.BUCHANAN |
| UT SOUTHWESTERN MEDICAL CENTER - SB | DALLAS, TX | $78,343 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR.BROWN |
| VANPELT BIOSCIENCES LLC | MONTGOMERY VILLAGE, MD | $75,000 | 2024 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.FORD |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $50,837 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR.REICHENBERG |
| THE REGENTS OF THE UNIV OF MINNESOTA | MINNEAPOLIS, MN | $40,875 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR. VINOGRADOV |
| THE RESEARCH FOUNDATION OF SUNY | SYRACUSE, NY | $17,390 | 2024 | TREATMENT TRIALS-EARMARKED FOR DR. WEICKERT |
| JOHNS HOPKINS UNIVERSITY - RHY | BALTIMORE, MD | $2,473,703 | 2023 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.YOLKEN |
| SHEPPARD PRATT | BALTIMORE, MD | $549,304 | 2023 | TREATMENT TRIALS-EARMARKED FOR DR.DICKERSON |
| UNIVERSITY OF MARYLAND BALTIMORE - RB | COLUMBIA, MD | $200,014 | 2023 | TREATMENT TRIALS-EARMARKED FOR DR.BUCHANAN |
| THE REGENTS OF THE UNIV OF CALIFORNIA | LOS ANGELES, CA | $148,083 | 2023 | TREATMENT TRIALS-EARMARKED FOR DR.MARDER |
| TREATMENT ADVOCACY CENTER | ARLINGTON, VA | $104,577 | 2023 | TAC GRANT FOR YEARLY EXPENSES |
| VANPELT BIOSCIENCES LLC | MONTGOMERY VILLAGE, MD | $75,000 | 2023 | NEUROVIROLOGY STUDIES-EARMARKED FOR DR.FORD |
| UT SOUTHWESTERN MEDICAL CENTER - SB | DALLAS, TX | $72,317 | 2023 | TREATMENT TRIALS-EARMARKED FOR DR.BROWN |
| UNIVERSITY OF PITTSBURGH | PITTSBURGH, PA | $49,465 | 2023 | TREATMENT TRIALS-EARMARKED FOR DR.NIMGAONKAR |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $33,042 | 2023 | TREATMENT TRIALS-EARMARKED FOR DR.REICHENBERG |
JOHNS HOPKINS UNIVERSITY - RHY
$2,564,105NEUROVIROLOGY STUDIES-EARMARKED FOR DR.YOLKEN
SHEPPARD PRATT
$588,013NEUROVIROLOGY STUDIES-EARMARKED FOR DR.DICKERSON
UNIVERSITY OF MARYLAND BALTIMORE - RB
$147,656TREATMENT TRIALS-EARMARKED FOR DR.BUCHANAN
THE REGENTS OF THE UNIV OF CALIFORNIA
$126,223TREATMENT TRIALS-EARMARKED FOR DR.MARDER
TREATMENT TRIALS-EARMARKED FOR DR.NIMGAONKAR AND DR.CHENGAPPA
TAC GRANT FOR YEARLY EXPENSES
THE MCLEAN HOSPITAL CORPORATION
$89,197TREATMENT TRIALS-EARMARKED FOR DR.ONGUR
VANPELT BIOSCIENCES LLC
$75,000TREATMENT TRIALS-EARMARKED FOR DR.NIMGAONKAR
TREATMENT TRIALS-EARMARKED FOR DR.MILLER
JOHNS HOPKINS UNIVERSITY - RHY
$2,525,950NEUROVIROLOGY STUDIES-EARMARKED FOR DR.YOLKEN
SHEPPARD PRATT
$599,262NEUROVIROLOGY STUDIES-EARMARKED FOR DR.DICKERSON AND TREATMENT TRIALS-EARMARKED FOR DR.DICKERSON
THE REGENTS OF THE UNIV OF CALIFORNIA
$114,254TREATMENT TRIALS-EARMARKED FOR DR.MARDER
UNIVERSITY OF MARYLAND BALTIMORE - RB
$101,570TREATMENT TRIALS-EARMARKED FOR DR.BUCHANAN
VANPELT BIOSCIENCES LLC
$75,000NEUROVIROLOGY STUDIES-EARMARKED FOR DR.FORD
TREATMENT TRIALS-EARMARKED FOR DR.REICHENBERG
THE REGENTS OF THE UNIV OF MINNESOTA
$40,875TREATMENT TRIALS-EARMARKED FOR DR. VINOGRADOV
THE RESEARCH FOUNDATION OF SUNY
$17,390TREATMENT TRIALS-EARMARKED FOR DR. WEICKERT
JOHNS HOPKINS UNIVERSITY - RHY
$2,473,703NEUROVIROLOGY STUDIES-EARMARKED FOR DR.YOLKEN
SHEPPARD PRATT
$549,304TREATMENT TRIALS-EARMARKED FOR DR.DICKERSON
UNIVERSITY OF MARYLAND BALTIMORE - RB
$200,014TREATMENT TRIALS-EARMARKED FOR DR.BUCHANAN
THE REGENTS OF THE UNIV OF CALIFORNIA
$148,083TREATMENT TRIALS-EARMARKED FOR DR.MARDER
VANPELT BIOSCIENCES LLC
$75,000NEUROVIROLOGY STUDIES-EARMARKED FOR DR.FORD
UT SOUTHWESTERN MEDICAL CENTER - SB
$72,317TREATMENT TRIALS-EARMARKED FOR DR.BROWN
TREATMENT TRIALS-EARMARKED FOR DR.REICHENBERG
